{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-24-000047","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.251052+00:00","generated_at":"2026-06-02T07:16:03.489382+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biohaven Q1 net loss $179.5M ($2.20/shr) vs $70.5M loss a year ago; cash $287.6M plus $247.8M from April offering","bullets":["Net loss $179.5M ($2.20/shr); non-GAAP adjusted net loss $144.6M ($1.77/shr); both more than doubled vs Q1 2023.","R&D expense $156.0M, up 146% YoY, driven by advancing trials and $16.6M in shares for Pyramid Biosciences acquisition.","Cash, equivalents and marketable securities $287.6M at March 31; additional $247.8M from April 2024 public offering of 6.45M shares at $41.","FDA granted rare pediatric disease designation for taldefgrobep alfa in SMA; Phase 3 data expected 2H 2024.","Phase 2/3 programs initiated with Kv7 activator BHV-7000 in epilepsy, MDD, and bipolar; BHV-1300 MoDE shows IgG reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-24-000047","json":"https://secwatch.observer/filing/0001935979-24-000047.json","markdown":"https://secwatch.observer/filing/0001935979-24-000047.md","text":"https://secwatch.observer/filing/0001935979-24-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597924000047/0001935979-24-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597924000047/bhvn-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:16:03.489382+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b87eef9481b48f20d70fb995e79923d26a954fec","claim":"Biohaven Ltd. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a review of recent accomplishments and anticipated upcoming developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597924000047/0001935979-24-000047-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}